Medical Pharmaceutical Supply – Dextrose and Sodium Chloride Injection

The contract requires the supply of sterile Dextrose and Sodium Chloride Injection, an intravenous solution regulated by the FDA and manufactured in full compliance with current Good Manufacturing Practices. The product must meet rigorous military standards, including MIL-STD-129 packaging requirements and specific technical specifications outlined by the Defense Logistics Agency. This subcontract is part of the Medical Supply Chain Pharm FSA’s effort to ensure consistent, high-quality sterile injectable supply for Department of Defense medical operations. All deliveries are expected to be performed at the FPO postal address with ZIP code 96692, and the solution must maintain sterility, purity, and stability throughout the supply chain. The solicitation was posted on July 12, 2026, with a firm response deadline of July 20, 2026. No set-aside designation is specified, meaning eligible contractors of any size may respond. The North American Industry Classification System code 325412 identifies the relevant manufacturing sector for pharmaceutical preparations. The contract is managed under the Department of Defense’s medical logistics framework and can be accessed via the DIBBS platform at the provided link. Compliance with all regulatory, technical, and packaging standards is mandatory, and failure to adhere to these requirements may result in rejection or contract default.